Written by the wedopeptides Research Team
MOTS-c vs Retatrutide: At a Glance
MOTS-c is a mitochondrial-derived peptide studied around the AMPK energy-sensing pathway. Retatrutide is an investigational incretin triple agonist. Both are metabolic-research compounds, but one acts at the level of mitochondrial signalling and the other at incretin/hormone receptors.
Research use only. Both compounds are supplied for in-vitro laboratory research. Neither is a medicine, and neither is for human or veterinary consumption, administration, or therapeutic use.
How They Work — The Key Difference
MOTS-c is studied as an endogenous signalling peptide that influences cellular energy metabolism via AMPK. Retatrutide is an engineered receptor agonist that activates three hormone receptors (GLP-1, GIP, glucagon). One is studied as an internal metabolic regulator; the other as an external multi-receptor agonist.
Evidence & Regulatory Status
MOTS-c research is largely preclinical with limited human data; retatrutide is investigational and in Phase 3 trials. Neither is an approved medicine in the UK, and research-grade material of either is supplied for laboratory use only.
Sourcing for Research
See our individual guides for full background, and verify purity against a batch-matched COA. View MOTS-c and Retatrutide product details.
Frequently Asked Questions
What is the difference between MOTS-c and Retatrutide?+
Are MOTS-c or Retatrutide approved?+
Why are both grouped under metabolic research?+
Related Guides
Products discussed in this guide are for research and laboratory use only. wedopeptides does not condone or support misuse of any research materials. Not for human or animal consumption.